ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Personalis Inc

Personalis Inc (PSNL)

9,75
-0,29
(-2,89%)
Geschlossen 10 Juni 10:00PM
9,45
-0,30
(-3,08%)
Nach Börsenschluss: 1:43AM

Personalis Inc (PSNL) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
9,45
( -5,88% )
Gebot
9,29
Fragen
9,60
Volumen
4.011.496
9,08 Tagesbereich 10,20
3,84 52-Wochen-Bereich 12,53
Marktkapitalisierung
Handelsende
10,04
Handelsbeginn
10,06
Letzte Trade
5
@
9.6
Letzter Handelszeitpunkt
Finanzvolumen
US$ 38.815.838
VWAP
9,6762
Durchschnittliches Volumen (3 Mio.)
US$ 2.214.306
Ausgegebene Aktien
104.721.098
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-10,51
Gewinn pro Aktie (EPS)
-1,02
Erlöse (LTM)
64,52M
Nettogewinn (LTM)
-95,55M

Über Personalis Inc

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in soli... Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company’s customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. Mehr anzeigen

Sektor
Healthcare
Branche
Medical Diagnostics & Screening
Hauptsitz
Fremont, United States
Gegründet
2026
Personalis Inc is listed in the Healthcare sector of the NASDAQ with ticker PSNL. The last closing price for Personalis was US$10,04. Over the last year, Personalis shares have traded in a share price range of US$ 3,84 to US$ 12,53.

Personalis currently has 104.721.098 shares in issue. The market capitalisation of Personalis is US$989,61 million. Personalis has a price to earnings ratio (PE ratio) of -10.51.

PSNL Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.57-14.246823956411.0212.539.45347087411.14489019CS
43.6663.21243523325.7912.535.731562519.26005966CS
122.6238.36017569556.8312.534.95522579507.63312176CS
26-0.26-2.677651905259.7112.534.95518185638.06729671CS
524.1578.30188679255.312.533.8415559367.70410454CS
1567.32343.6619718312.1312.530.89069732035.85729533CS
260-13.24-58.351696782722.6928.470.89067666016.51322412CS

PSNL - Frequently Asked Questions (FAQ)

What is the current Personalis Inc share price?
The current share price of Personalis Inc is US$ 9,45
How many Personalis Inc shares are in issue?
Personalis Inc has 104.721.098 shares in issue
What is the market cap of Personalis Inc?
The market capitalisation of Personalis Inc is USD 989,61M
What is the 1 year trading range for Personalis Inc share price?
Personalis Inc has traded in the range of US$ 3,84 to US$ 12,53 during the past year
What is the PE ratio of Personalis Inc?
The price to earnings ratio of Personalis Inc is -10,51
What is the cash to sales ratio of Personalis Inc?
The cash to sales ratio of Personalis Inc is 17,45
What is the registered address of Personalis Inc?
The registered address for Personalis Inc is 6600 Dumbarton Circle, Fremont, California, 94555
What is the Personalis Inc website address?
The website address for Personalis Inc is www.personalis.com
Which industry sector does Personalis Inc operate in?
Personalis Inc operates in the Medical Diagnostics & Screening sector

PSNL Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen